{"transactions":[{"id":684100,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant","published_at":"2026-08-18T10:06:07.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":true,"shares":254307,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169."}],"balance_after":289836,"derivative":{"exercise_price":0.484,"exercise_date":"2026-04-23","expiration_date":"2028-04-23","underlying":"Common Stock","underlying_shares":254307},"source":{"system":"sec-edgar","filing":"0001493152-26-038866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315226038866/ownership.xml","form_type":"4"}},{"id":684099,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T10:06:07.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":0.495,"value":198000.0,"ownership":{"direct":true},"balance_after":916740,"source":{"system":"sec-edgar","filing":"0001493152-26-038866","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315226038866/ownership.xml","form_type":"4"}},{"id":684098,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T10:06:07.000Z","date":"2026-04-23","kind":"purchase","planned":false,"acquired":true,"shares":508614,"price":0.484,"value":246169.176,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person."}],"balance_after":516740,"source":{"system":"sec-edgar","filing":"0001493152-26-038866","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315226038866/ownership.xml","form_type":"4"}},{"id":1969649,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-06T21:33:15.000Z","date":"2023-03-02","kind":"purchase","acquired":true,"shares":90287,"price":0.4883,"value":44087.1421,"ownership":{"direct":true},"balance_after":1222682,"source":{"system":"sec-edgar","filing":"0001493152-23-006786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223006786/ownership.xml","form_type":"4"}},{"id":1980393,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-02T20:45:52.000Z","date":"2023-03-01","kind":"purchase","acquired":true,"shares":270000,"price":0.4777,"value":128979.0,"ownership":{"direct":true},"balance_after":1132395,"source":{"system":"sec-edgar","filing":"0001493152-23-006553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223006553/ownership.xml","form_type":"4"}},{"id":1980392,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-02T20:45:52.000Z","date":"2023-02-28","kind":"purchase","acquired":true,"shares":109300,"price":0.4883,"value":53371.19,"ownership":{"direct":true},"balance_after":862395,"source":{"system":"sec-edgar","filing":"0001493152-23-006553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223006553/ownership.xml","form_type":"4"}},{"id":2038771,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2023-02-01T23:06:45.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":714286,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On October 28, 2022, Ensysce Biosciences, Inc. (the \"Company\"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the \"Common Stock\")."},{"field":"security","element":"securityTitle","label":"F3","text":"On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the \"Warrants\") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the \"Warrants\") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the \"Warrants\") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the \"Warrants\") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance."}],"balance_after":716365,"derivative":{"exercise_price":1.4,"expiration_date":"2027-12-09","underlying":"Common Stock","underlying_shares":714286},"source":{"system":"sec-edgar","filing":"0001493152-23-003343","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223003343/ownership.xml","form_type":"4"}},{"id":2038770,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-01T23:06:45.000Z","date":"2022-12-09","kind":"purchase","acquired":true,"shares":357143,"price":1.4,"value":500000.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On October 28, 2022, Ensysce Biosciences, Inc. (the \"Company\"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the \"Common Stock\")."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share."}],"balance_after":753095,"source":{"system":"sec-edgar","filing":"0001493152-23-003343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315223003343/ownership.xml","form_type":"4"}},{"id":2221412,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T21:40:22.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":41585,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017876","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315222017876/ownership.xml","form_type":"4"}},{"id":2411893,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2022-02-04T20:18:02.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Gower was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."}],"balance_after":20000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-22-003208","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000149315222003208/ownership.xml","form_type":"4"}},{"id":2645437,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2021-07-02T22:15:31.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":6585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":6585,"derivative":{"exercise_price":2.59,"expiration_date":"2029-03-14","underlying":"Common Stock","underlying_shares":6585},"source":{"system":"sec-edgar","filing":"0001192482-21-000620","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000119248221000620/edgar.xml","form_type":"4"}},{"id":2645436,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":22410,"kind":"person","name":"GOWER BOB G","position":1,"cik":"0001136466","reported_name":"GOWER BOB G","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T22:15:31.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":7919026,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock."}],"balance_after":7919026,"source":{"system":"sec-edgar","filing":"0001192482-21-000620","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136466/000119248221000620/edgar.xml","form_type":"4"}}]}